SCHEMBL17834342

SCHEMBL17834342

CCC(C)N1C(=O)S/C(=C\c2ccc(Sc3nc4ccccc4[nH]3)o2)C1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MYC P01106 16/20 1.00
MEN1 O00255 4/20 1.00
KMT2A Q03164 4/20 1.00
SMN1; SMN2 Q16637 4/20 1.00
ALDH1A1 P00352 3/20 1.00
LMNA P02545 3/20 1.00
HTT P42858 2/20 1.00
HPGD P15428 2/20 1.00
KDM4E B2RXH2 1/20 1.00
CYP1A2 P05177 1/20 1.00
GLA P06280 1/20 1.00
CYP3A4 P08684 1/20 1.00
CYP2D6 P10635 1/20 1.00
CYP2C9 P11712 1/20 1.00
CYP2C19 P33261 1/20 1.00
MAPT P10636 2/20 0.83
MAPK1 P28482 2/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17834254 1.00 MYC (1.00) MYCMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL17834334 1.00 MYC (1.00) MYCMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL17834352 0.91 MYC (1.00) MYCMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL17821363 0.91 MYC (1.00) MYCMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL17821362 0.91 MYC (1.00) MYCMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL17834251 0.89 MYC (0.80) MYCMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL17834329 0.88 MYC (0.85) MYCMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL20362879 0.87 MYC (0.77) MYCMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL17834253 0.85 MEN1 (1.00) MYCMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL17834351 0.85 MEN1 (1.00) MYCMEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200048276-A9 MYC MODULATORS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2020-02-13 US disclosed
US-10017520-B2 Myc modulators and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2018-07-10 US disclosed
US-20160168165-A1 MYC MODULATORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-06-16 US disclosed
WO-2016094688-A1 FUSED 1,3-AZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2016-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168165-A1 MYC MODULATORS AND USES THEREOF MYC, MYCBP, MYCBP2 MYC 1/4885MEN1 336/4885KMT2A 1253/4885
US-20200048276-A9 MYC MODULATORS AND USES THEREOF MYC, MYCBP, MYCBP2 MYC 1/4885MEN1 336/4885KMT2A 1253/4885
US-10017520-B2 Myc modulators and uses thereof MYC, MYCBP, MYCBP2 MYC 1/4885MEN1 336/4885KMT2A 1253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.